NCT03757351View on ClinicalTrials.gov

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

DNL747

Repeating oral dose

DRUG

Placebo

Repeating oral dose

Trial Locations (3)

2333

CHDR, Leiden

32806

Bioclinica, Orlando

84124

PRA Health Sciences, Salt Lake City

Sponsors

Lead Sponsor

Sanofi

Collaborators (1)

Denali Therapeutics Inc.
All Listed Sponsors
collaborator

Denali Therapeutics Inc.

INDUSTRY

lead

Sanofi

INDUSTRY

NCT03757351 - Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter